~~<i id='E71FDE5F7F'><strike id='E71FDE5F7F'><tt id='E71FDE5F7F'><pre id='E71FDE5F7F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：comprehensive 2025-09-07 04:07:44 - browse：14861

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： STAT Virtual Event: ASCO Recap, Live!

entertainment

Wikipedia

explore

leisure time

explore

entertainment

AdobeMorethan100,000doctorshave leftprivate practice andbecomeemployeesofhospitalsandothercorporatee

WSS

Lilly's Alzheimer's drug donanemab backed by FDA advisers

STAT Boddities: What happens to the brain when we get scared?

Report cites 'urgent' need to recruit more diverse clinical trial participants

Having children helps parents live longer, especially after age 80

Artificial intelligence use in health care faces greater scrutiny in 2024

Juul documents reveal insider tactics on political lobbying

entertainment

explore

entertainment

Heart attack and stroke risk calculators need revising

STAT Virtual Event: ASCO Recap, Live!

Tori Bowie and the unacceptable rates of Black maternal death

Bernie Sanders gets little from pharma CEOs on drug prices

BioMarin wins approval for gene therapy to treat hemophilia A

Statins may not be needed by millions of people, study suggests

Walensky prepares to leave CDC — and Congress — behind

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

The cancer drug shortage isn’t new — and neither are the solutions

Abbott's new heart device gets FDA advisory panel nod

Wikipedia

AMAs digital advisors table RPM coding reform proposal, again

My daughter's legacy lives on through her writing, phage therapy

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

STAT Virtual Event: ASCO Recap, Live!

Study: Why relieving medical debt did not improve financial outcomes

New report analyzes digital physical therapy solutions' effectiveness

explore

leisure time

explore

entertainment